Compound 36, a potent dual PDE4/7 inhibitor, exerted strong anti-TNF-α activity in vivo, which was manifested by a significant reduction in the maximum plasma concentration of TNF-α by 90.2% in LPS-induced endotoxemia in rats [21]. Here, PDE4A is linked to serum lipopolysaccharide activity.